SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
May 23 2024 - 5:00PM
Business Wire
- Patient enrollment and dosing ongoing in first-in-human
study of BOXR1030 enhanced CAR T-cell therapy
SOTIO Biotech, a clinical-stage immuno-oncology
company owned by PPF Group, will present on June 1, 2024
(Developmental Therapeutics—Immunotherapy session) a
Trial-in-Progress poster on the first-in-human DUET-01 Phase 1/2
study at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting. The study is evaluating the use of BOXR1030, a
metabolically enhanced CAR T-cell therapy, for the treatment of
patients with solid tumors.
Patient enrollment and dosing in the DUET-01 clinical trial
(NCT05120271) are ongoing at three leading cancer care centers
across the U.S., with additional sites expected to be imminently
initiated in the U.K.
“The arrival of CAR T-cell therapies has profoundly improved the
therapeutic outlook for patients with some blood cancers.
Unfortunately, the same has not been true for solid tumors, where
cell therapies’ success has been stymied by the challenges of
overcoming the tumor microenvironment,” said Ecaterina Dumbrava,
M.D., Assistant Professor of Investigational Cancer Therapeutics at
The University of Texas MD Anderson Cancer Center and primary
investigator on the DUET-01 trial. “As a metabolically enhanced
GPC3-targeting CAR T-cell therapy, BOXR1030 has shown promising
preclinical results in resisting tumor microenvironment-like
conditions and improving T cell proliferation compared with
standard CAR T cells. GPC3 is a clinically validated
tumor-restricted target with a high prevalence in several solid
tumor indications with unmet medical need. Given these promising
observations thus far, we are looking forward to continuing to
evaluate its potential in a clinical setting in the DUET-01
study.”
The DUET-01 clinical trial is a first-in-human, open-label,
multicenter, dose escalation study to assess and determine the
recommended Phase 2 dose of BOXR1030 in patients with GPC3-positive
advanced solid tumors. The trial will enroll up to 98 patients with
advanced, unresectable hepatocellular carcinoma, squamous cell lung
cancer, myxoid/round cell liposarcoma, and Merkel cell
carcinoma.
Presentation materials will be available on June 1, after
presentations conclude, here.
About SOTIO Biotech
SOTIO Biotech (SOTIO) is shaping the future of cancer
immunotherapies by translating compelling science into patient
benefit. The SOTIO pipeline includes SOT102, a next-generation
Claudin-18.2-targeted antibody-drug conjugate which entered the
clinic in 2022; BOXR1030, a metabolically enhanced CAR-T cell
therapy targeting GPC3-expressing tumors; as well as other
molecules approaching clinical stage such as SOT201, our
next-generation PD-1-inhibiting immunocytokine. SOTIO is a member
of the PPF Group. For more information, please visit the company’s
website at www.sotio.com.
SOTIO is a registered trademark of SOTIO Biotech a.s. in
selected countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523086119/en/
Company: Richard Kapsa Head of
Communication T: (+420) 224 174 448 M: (+420) 603 280
971 kapsa@sotio.com Media: Lisa Raffensperger Ten
Bridge Communications M: +1 (617) 903-8783
lisa@tenbridgecommunications.com